ClearView Wealth has lodged its Scheme Booklet with ASIC, outlining Zurich's $0.65-per-share takeover offer and setting the stage for a pivotal shareholder vote on 27 July 2026.
- Scheme Booklet registered by ASIC
- Independent Expert deems Scheme fair and reasonable
- ClearView Board unanimously recommends Scheme
- Crescent Capital Partners supports Scheme with 53% stake
- Scheme Meeting scheduled as hybrid event on 27 July 2026
Scheme Booklet Registered and Shareholder Meeting Set
ClearView Wealth Limited (ASX:CVW) has taken a significant step toward its acquisition by Zurich Financial Services Australia Limited, with the Scheme Booklet officially registered by the Australian Securities and Investments Commission (ASIC). The document lays out the terms of Zurich's proposed takeover, including a cash Scheme Consideration of $0.65 per ClearView share, subject to adjustments for dividends and potential increases if the deal's Effective Date falls on or after 30 September 2026.
The Scheme Meeting, where shareholders will vote on the transaction, is scheduled as a hybrid event for 10:00am (Sydney time) on Monday, 27 July 2026. ClearView shareholders can participate either in person at the company's Sydney office or online via a dedicated platform, reflecting a modern approach to shareholder engagement.
Independent Expert and Board Endorse Scheme
Grant Thornton Corporate Finance Pty Limited, the Independent Expert appointed by ClearView, has concluded that the Scheme is fair and reasonable and in the best interests of ClearView shareholders, provided no superior alternative proposal emerges. This assessment places the $0.65 offer within a valuation range of $0.625 to $0.764 per share on a control basis, though the expert notes the valuation is finely balanced due to market and operational uncertainties.
In line with this, the ClearView Board unanimously recommends shareholders vote in favour of the Scheme, emphasizing the attractive premium it represents compared to recent trading prices, a 21.5% premium to the last undisturbed closing price before the deal announcement. The Board highlights the certainty of cash liquidity and the opportunity for shareholders to realise their investment at a premium to market prices.
Major Shareholder Crescent Capital Partners Backs Deal
Backing the transaction is ClearView’s largest shareholder group, Crescent Capital Partners, which controls approximately 53% of ClearView shares. Crescent Capital has formally notified the ClearView Board of its intention to vote all its shares in favour of the Scheme, contingent on the Board’s continued recommendation and the Independent Expert’s ongoing support, as well as the absence of any superior proposal. This substantial support significantly bolsters the likelihood of Scheme approval.
Zurich’s Intentions and Regulatory Approvals
Zurich plans to maintain ClearView Life Assurance’s business as a separate entity for about six months post-implementation, after which it will integrate new life insurance policies under the Zurich, OnePath Life, and ClearView brands. The acquisition is contingent on several conditions precedent, including the requisite shareholder and Court approvals, as well as regulatory clearances from the Australian Prudential Regulation Authority (APRA) and the Australian Competition and Consumer Commission (ACCC), both of which remain pending.
The transaction also includes customary exclusivity provisions and break fees of approximately $4.18 million payable under certain circumstances, underscoring the deal’s seriousness and the parties’ commitment.
What Shareholders Should Watch Next
ClearView shareholders face a critical decision at the upcoming Scheme Meeting. The offer provides a clear premium and liquidity, but voting against the Scheme remains an option for those who prefer to maintain exposure to ClearView’s standalone prospects or anticipate a superior offer. The risk of the Scheme not proceeding includes potential share price volatility and uncertainty about ClearView’s future as a listed entity.
Investors should monitor the progress of regulatory approvals, the Scheme Meeting outcome, and any emerging proposals that could rival Zurich’s bid. The Scheme Booklet, now available, offers detailed information and encourages shareholders to seek independent advice tailored to their circumstances.
Bottom Line?
The Scheme Booklet registration marks a key milestone, but shareholder and regulatory approvals remain the hurdles before Zurich’s acquisition of ClearView can be sealed.
Questions in the middle?
- Will any superior proposal emerge before the Scheme Meeting?
- How will APRA’s final approval timing affect the Scheme’s implementation?
- What are the tax implications for shareholders receiving the Special Dividend and Scheme Consideration?